Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $26 on Ariad Pharmaceuticals on Tempered Iclusig Outlook

Share:
Related ARIA
Incyte Could Be A Takeover Target, Argus Lifts Price Target To $98
Ariad's Recent Run Has Stock At Highest Levels Since October 2013
Biotech: What's Next For M&A? (Seeking Alpha)

Stifel Nicolaus maintained Ariad Pharmaceuticals (NASDAQ: ARIA) with a Buy rating and lowered the price target from $27.00 to $26.00.

Stifel Nicolaus noted, "We surveyed 34 hematology/oncology specialists in February. Results continue to suggest best-in-class potential for Iclusig in third-line and later-line therapy but greater uncertainty than before regarding Iclusig's front-line potential on the heels of black box warnings for thrombosis and hepatotoxicity. We decrease our target price to $26 from $27 as we decrease our Iclusig sales and out-year EPS estimates."

Ariad Pharmaceuticals closed at $20.08 on Wednesday.

Latest Ratings for ARIA

DateFirmActionFromTo
Sep 2016Leerink SwannInitiates Coverage onOutperform
Jul 2016BarclaysMaintainsUnderweight
May 2016Cowen & Co.UpgradesMarket PerformOutperform

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARIA)

View Comments and Join the Discussion!